Abstract (summary)

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
금요일, 3월 8, 2024

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.

Key Points: 
  • NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
  • Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49 .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
수요일, 3월 6, 2024

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
수요일, 2월 28, 2024

Announced appointment of Mardi C. Dier as Chief Financial Officer

Key Points: 
  • Announced appointment of Mardi C. Dier as Chief Financial Officer
    Anticipates resmetirom to become the first medicine approved for NASH; PDUFA date March 14, 2024
    CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports fourth quarter and full year 2023 financial results.
  • She has held CFO positions at Portola Pharmaceuticals, Ultragenyx, and Acelyrin.
  • Five Madrigal health economic abstracts were presented at the NASH-TAG conference, which took place January 4-6, 2024 in Park City, Utah.
  • Financial Results for the Three and Twelve Months Ended December 31, 2023
    As of December 31, 2023, Madrigal had cash, cash equivalents and marketable securities of $634.1 million, compared to $358.8 million at December 31, 2022.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Retrieved on: 
화요일, 2월 20, 2024

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29 – March 2, 2024, in West Palm Beach, Florida.

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29 – March 2, 2024, in West Palm Beach, Florida.
  • Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Barry Singer, MD, The MS Center for Innovations in Care - Missouri Baptist Medical Center, St. Louis, MO
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
월요일, 3월 4, 2024

Key highlights of Better Therapeutics’ participation at ATTD include:

Key Points: 
  • Key highlights of Better Therapeutics’ participation at ATTD include:
    The late-breaking abstract findings further validate the use of AspyreRx ™ as a safe and effective treatment for patients with type 2 diabetes (T2D).
  • Abstract Title: Randomized, Controlled Trial Of A Novel Digital Therapeutic In Patients With Type 2 Diabetes: BT-001 Pivotal Trial 180 Day Outcomes
    Abstracts will be published in the peer-reviewed Journal of Diabetes Technology & Therapeutics.
  • Additionally, Better Therapeutics will host a sponsored industry symposium on Saturday, March 09, 2024, at 8:30 a.m. local time (CET).
  • Attendees will have the opportunity to experience AspyreRx firsthand and learn more about its clinical benefits at the Better Therapeutics exhibition booth.

University of Phoenix College of Doctoral Studies Releases New Edition of Phoenix Scholar™ Academic Periodical

Retrieved on: 
월요일, 2월 26, 2024

University of Phoenix College of Doctoral Studies has released the Winter 2023-2024 edition of its Phoenix Scholar™ academic research periodical.

Key Points: 
  • University of Phoenix College of Doctoral Studies has released the Winter 2023-2024 edition of its Phoenix Scholar™ academic research periodical.
  • The periodical, launched in 2017, highlights the commitment of University of Phoenix faculty, students and alumni to leading research through evidence-based practice.
  • “We are pleased to present a special anthology edition celebrating the 10th anniversary of our Knowledge Without Boundaries Summit,” shares Hinrich Eylers, Ph.D., P.E., vice provost, College of Doctoral Studies.
  • The College of Doctoral Studies research centers contribute to the publication findings: CLSOR, Center for Educational and Instructional Technology Research (CEITR), Center for Workplace Diversity and Inclusion Research (CWDIR), and the University of Phoenix Career Institute®.

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Retrieved on: 
금요일, 2월 23, 2024

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.

Key Points: 
  • AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.
  • Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA).
  • Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
  • A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON).

SCTE® Opens Call for Papers for TechExpo 2024

Retrieved on: 
화요일, 2월 13, 2024

EXTON, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Society of Cable Telecommunications Engineers (SCTE®), a CableLabs ® subsidiary, opens its call for papers today for presentation proposals for technical sessions that will be conducted during SCTE TechExpo 2024 , which will take place in Atlanta, Georgia, from September 24-26, 2024.

Key Points: 
  • EXTON, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Society of Cable Telecommunications Engineers (SCTE®), a CableLabs ® subsidiary, opens its call for papers today for presentation proposals for technical sessions that will be conducted during SCTE TechExpo 2024 , which will take place in Atlanta, Georgia, from September 24-26, 2024.
  • Each SCTE TechExpo abstract submission should be entered separately at expo.scte.org/callforpapers by April 5, 2024.
  • Registration for TechExpo will open on March 28, 2024, at the close of CableLabs’ Winter Conference .
  • For general questions regarding TechExpo technical workshops or the abstract submission process, please email [email protected] .

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
수요일, 2월 7, 2024

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

Retrieved on: 
월요일, 2월 5, 2024

Abstracts will be available on the meeting website today, February 5, 2024.

Key Points: 
  • Abstracts will be available on the meeting website today, February 5, 2024.
  • Abstract Title: Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial
    The abstract is comprised of the topline 12-week primary endpoint results the Company disclosed on November 6, 2023.
  • The Company will host a webcast presentation of the data on Sunday, February 25th at 9:45 AM ET.
  • The event will be webcast live and can be accessed by going to the "Events & Presentations” page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com .